Library — CHDR

Search

Filter

Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes.

Heuberger JAAC, Posthuma JJ, Ziagkos D, Rotmans JI, Daniels JMA, Gal P, Stuurman FE, Spronk HMH, Ten Cate H, Burggraaf J, Moerland M, Cohen AF

European journal of applied physiology, 2020 Aug; 120(8):1893-1904

View publication
Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implications.

Cohen AF, Burggraaf K, de Boer A, Kluft C

Annals of the New York Academy of Sciences, 2018 Dec

View publication
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.

Ducore J, Lawrence JB, Simpson M, Boggio L, Bellon A, Burggraaf J, Stevens J, Moerland M, Frieling J, Reijers J, Wang M

Haemophilia : the official journal of the World Federation of Hemophilia, 2018 Feb; 23(6):844-851

View publication
A PK-PD model-based assessment of sugammadex effects on coagulation parameters.

Bosch R, van Lierop MJ, de Kam PJ, Kruithof AC, Burggraaf J, de Greef R, Visser SA, Johnson-Levonas AO, Kleijn HJ

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016 Mar

View publication
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.

De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD, Langdon RB, Gutstein DE, Burggraaf J, El Galta R

International journal of clinical pharmacology and therapeutics, 2014 Jul; 52(8):631-41

View publication
Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.

De Kam PJ, Grobara P, Prohn M, Höppener F, Kluft C, Burggraaf J, Langdon RB, Peeters P

International journal of clinical pharmacology and therapeutics, 2014 Feb; 52(3):227-36

View publication
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.

de Kam PJ, El Galta R, Kruithof AC, Fennema H, van Lierop MJ, Mihara K, Burggraaf J, Moerland M, Peeters P, Troyer MD

International journal of clinical pharmacology and therapeutics, 2013 Nov; 51(12):976-85

View publication
Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.

Kluft C, Meijer P, Kret R, Burggraaf J

International journal of laboratory hematology, 2013 Jul; 35(4):379-84

View publication
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Heuberger JA, Cohen Tervaert JM, Schepers FM, Vliegenthart AD, Rotmans JI, Daniels JM, Burggraaf J, Cohen AF

British journal of clinical pharmacology, 2013 May; 75(6):1406-21

View publication

«
1
2
3
4
5
6
»